We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Successful Treatment of Interstitial Lung Disease in STAT3 Gain-of-Function Using JAK Inhibitors.
- Authors
Silva-Carmona, Manuel; Vogel, Tiphanie P.; Marchal, Sarah; Guesmi, Myriam; Dubus, Jean-Christophe; Leroy, Sylvie; Fabre, Alexandre; Barlogis, Vincent; Forbes, Lisa R.; Giovannini-Chami, Lisa
- Abstract
The article discusses the successful Treatment of Interstitial Lung Disease (ILD) in STAT3 Gain-of-Function Using JAKs (Janus kinases) Inhibitors. Topics include four patients with STAT3 GOF with ILD treated with JAK inhibitors, two with ruxolitinib and two with tofacitinibpatients; and showing that JAK inhibitors, on being combined with tocilizumab or being used as monotherapy is safe and effective in four patients with STAT3 GOF mutations.
- Subjects
INTERSTITIAL lung diseases; JANUS kinases; PATIENTS; TOCILIZUMAB; GAIN-of-function mutations
- Publication
American Journal of Respiratory & Critical Care Medicine, 2020, Vol 202, Issue 6, p893
- ISSN
1073-449X
- Publication type
case study
- DOI
10.1164/rccm.201906-1204LE